Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Two Dose Regimens of Becocalcidiol in the Treatment of Plaque-Type Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of stable plaque-type psoriasis affecting 2% to 10% of the subject's body surface area~* Psoriasis of a severity that is appropriate for treatment with topical therapy; PGA of at least 3 (moderate) at baseline; PSS of at least 7, and with no individual symptom score (erythema, induration, or scaling) less than 2~* Subject must sign the IRB approved informed consent and agree to follow dosing instructions and complete required clinic visits.~Exclusion Criteria:~* Pregnant or nursing females~* Systemic corticosteroids, methotrexate, cyclosporine, systemic retinoids, prolonged sun exposure or ultraviolet light therapy within 4 weeks of dosing~* Topical corticosteroids, retinoids, calcipotriene, coal tar, anthralin, or any other treatment indicated for psoriasis within 2 weeks of dosing~* Untreated bacterial, tubercular, fungal or any viral lesion of the skin~* Biologic agents/monoclonal antibodies in the last 6 months~* Currently using lithium or plaquenil~* Currently using a beta-blocking medication or thiazide diuretic and the dose has not been stabilized for at least 6 months~* History of hypercalcemia or evidence of vitamin D toxicity~* Current or history of melanoma skin cancer in the past 5 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).